Novazyme Pharmaceuticals Overview

  • Year Founded
  • 1999

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $215M

Novazyme Pharmaceuticals General Information

Description

Developer of biotherapeutic products for the treatment of lysosomal storage disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 353 Nassau Street
  • Princeton, NJ 08540
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novazyme Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 27-Sep-2001 $215M 0000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 18-Apr-2001 0000 0000 Completed Generating Revenue
1. Early Stage VC (Series A) 19-Sep-2000 $8M $8M Completed Product Development
To view Novazyme Pharmaceuticals’s complete valuation and funding history, request access »

Novazyme Pharmaceuticals Patents

Novazyme Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-7135322-B2 In mammalian cells deficient in furin proteolytic enzyme Inactive 21-Dec-2001 00000000 00
US-20030148460-A1 N-acetylglucosaminidase for treating organelle storage disease such as fabry disease Active 14-Sep-1999 0000000000 00

Novazyme Pharmaceuticals Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
Catalyst Health Ventures Venture Capital Minority 000 0000 000000 0
HealthCare Ventures Venture Capital Minority 000 0000 000000 0
Morgan Stanley Expansion Capital Growth/Expansion Majority 000 0000 000000 0
Strattech Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Novazyme Pharmaceuticals FAQs

  • When was Novazyme Pharmaceuticals founded?

    Novazyme Pharmaceuticals was founded in 1999.

  • Where is Novazyme Pharmaceuticals headquartered?

    Novazyme Pharmaceuticals is headquartered in Princeton, NJ.

  • What industry is Novazyme Pharmaceuticals in?

    Novazyme Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Novazyme Pharmaceuticals a private or public company?

    Novazyme Pharmaceuticals is a Private company.

  • What is the current valuation of Novazyme Pharmaceuticals?

    The current valuation of Novazyme Pharmaceuticals is 00000.

  • What is Novazyme Pharmaceuticals’s current revenue?

    The current revenue for Novazyme Pharmaceuticals is 000000.

  • How much funding has Novazyme Pharmaceuticals raised over time?

    Novazyme Pharmaceuticals has raised $24M.

  • Who are Novazyme Pharmaceuticals’s investors?

    Aisling Capital, Catalyst Health Ventures, HealthCare Ventures, Morgan Stanley Expansion Capital, and Strattech Partners are 5 of 6 investors who have invested in Novazyme Pharmaceuticals.

  • When was Novazyme Pharmaceuticals acquired?

    Novazyme Pharmaceuticals was acquired on 27-Sep-2001.

  • Who acquired Novazyme Pharmaceuticals?

    Novazyme Pharmaceuticals was acquired by Sanofi Genzyme.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »